Virbac, a prominent player in the global animal health industry, has recently announced a significant agreement to acquire Globion, a leading specialist in poultry vaccines based in India. This strategic move is poised to enhance Virbac’s leadership in the Indian animal health market by expanding its poultry portfolio into the rapidly growing segment of avian vaccines.
Founded in 2005 as a joint venture between Suguna Group, a major Indian poultry conglomerate, and Lohmann Animal Health, a German specialist in poultry vaccines, Globion has emerged as a key player with robust know-how and expertise in the development, manufacturing, and commercialization of live and inactivated vaccines targeting a diverse range of avian pathogens.
Globion, headquartered in Hyderabad, operates with approximately 120 full-time employees and boasts industrial and R&D facilities. With an annual revenue of around €12 million, the company has been independently run by a professional team dedicated to advancing the field of avian health.
Sébastien Huron, the CEO of Virbac Group, expressed enthusiasm about the acquisition, stating, “We are extremely pleased and honored to welcome the Globion team within our Virbac family. This acquisition illustrates our 2030 Virbac vision and ambition to grow through ‘programmatic’ M&A, investing in vaccines—a key strategic axis of development. It reinforces our leadership position in India, the world’s most populous country, and completes our portfolio targeting the dynamic and promising poultry market.”
Huron further emphasized Virbac’s commitment to supporting the Globion team, providing them with additional resources to maximize their performance. He highlighted the shared ambition with Suguna and Globion teams to create long-term value for customers, drive innovation, and build a competitive portfolio of products supporting the poultry industry in India and beyond.
B.Soundararajan, the founder and managing director of Suguna Group, expressed satisfaction with the strategic partnership, stating, “Virbac comes out as the right choice for us since Virbac and Suguna share a common vision of adding value to the poultry industry, and Virbac’s acquisition of Globion is a significant step in that direction.”
Soundararajan highlighted the transformation of Globion into a fast-growing poultry biologicals company, reaching over 1 billion rupees in revenues. He sees immense potential for Globion under Virbac’s ownership, leveraging Virbac’s long-term vision, infrastructure, and deep understanding of animal health in Indian and global markets.
The founder of Suguna Group also affirmed their continued partnership, stating, “We will continue to remain a key customer of Globion/Virbac in the future, and our best wishes to both Globion/Virbac teams for continued success.”
